Clin Cancer Res 30:4957–4973.This reference is of importance as it defined novel genetic drivers (YAP1, KRAS) and vulnerabilities in high-grade sarcoma models, linking specific oncogenic programmes to sarcoma subtypes and revealing oxidative phosphorylation as a potential therapeutic target. Here, KRAS is linked to sarcoma.